TY  - JOUR
AU  - Ulrich, Bryan C.
AU  - Guibert, Nicolas
PY  - 2018
TI  - Immunotherapy efficacy and gender: discovery in precision medicine
JF  - Translational Lung Cancer Research; Vol 7, Supplement 3 (September 26, 2018): Translational Lung Cancer Research1
Y2  - 2018
KW  - 
N2  - Immunotherapy is transforming the care of cancer. In the past five years, checkpoint blockade agents targeting the PD-1/PD-L1 checkpoint (e.g., nivolumab, pembrolizumab) have garnered FDA approvals in diverse indications including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and more (1-5). While these agents produce durable responses for some patients, the science of identifying responders remains inexact; further work is needed to identify biomarkers which better predict patient response than current clinical practice.
UR  - https://tlcr.amegroups.org/article/view/23547